Compare MINISO Group Holding Ltd (MNSO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Tango Therapeutics Inc. — how do they compare? MINISO Group Holding Ltd trades at $10.34 (market cap $2.89B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 6.71% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Tango Therapeutics Inc. for 0 Days on average.
| MNSO | TNGX | |
|---|---|---|
Market Cap | $2.89B | $3.75B |
Volume | 1,658,211 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $32.90 |
52-Week Low | $8.60 | $7.50 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $3.76B | $2.77B |
Dividend Yield | 6.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.92, up 1.95% with a bullish technical signal despite mixed earnings history. The company shows solid fundamentals with $21.44B revenue, 5.35% net margin, and attractive valuation ratios including P/E of 16.11 and P/S of 0.86. Recent CFO share purchases and analyst optimism (60% buy rating) support positive sentiment, though earnings misses in three of the last four quarters highlight execution risks amid competitive retail pressures.
The outlook remains cautiously optimistic given MNSO's valuation appeal and growth potential, but investors should monitor earnings consistency and overseas margin pressures. Key opportunities include domestic expansion and operational optimization, while risks involve volatile quarterly performance and intense retail competition.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
